Evidence map›Paper›PMID 24831821›Full record

ArticlePloS one2014

Simultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats.

Gina Youcef, Arnaud Olivier, Clément P J L'Huillier, Carlos Labat, Renaud Fay, Lina Tabcheh, Simon Toupance, Rosa-Maria Rodriguez-Guéant, Damien Bergerot, Frédéric Jaisser and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension.Journal of the mechanical behavior of biomedical materials · 2016
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Gina YoucefUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; Genomics Research Unit, Centre de Recherche Public de la Santé, Strassen, Luxembourg.
Arnaud OlivierUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CHU Nancy, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Clément P J L'HuillierUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France.
Carlos LabatUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France.
Renaud FayCHU Nancy, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Lina TabchehFédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; UMR 7365 CNRS, Vandoeuvre-lès-Nancy, France.
Simon ToupanceUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CHU Nancy, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Rosa-Maria Rodriguez-GuéantFédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CHU Nancy, Nancy, France; U954 Inserm, Vandoeuvre-lès-Nancy, France.
Damien BergerotCIC 9201, PARCC, HEGP, Paris, France.
Frédéric JaisserCHU Nancy, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Patrick LacolleyUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CHU Nancy, Nancy, France.
Faiez ZannadUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CHU Nancy, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Laurent VallarGenomics Research Unit, Centre de Recherche Public de la Santé, Strassen, Luxembourg.
Anne PizardUMRS U1116 Inserm, Vandoeuvre-lès-Nancy, France; Fédération de Recherche 3209, Nancy, France; Université de Lorraine, Nancy, France; CIC 1433, Pierre Drouin, Vandoeuvre-lès-Nancy, France.
Inserm · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre National de la Recherche Scientifique · FRLaboratoire National de Santé · LUParis Cardiovascular Research Center · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with metabolic syndrome (MetS) are prone to develop heart failure (HF). However, the deleterious effects of MetS on the continuum of events leading to cardiac remodeling and subsequently to HF are not fully understood. This study characterized simultaneously MetS and cardiac, vascular and renal phenotypes in aging Spontaneously Hypertensive Heart Failure lean (SHHF(+/?) regrouping (+/+) and (+/cp) rats) and obese (SHHF(cp/cp), "cp" defective mutant allele of the leptin receptor gene) rats. We aimed to refine the milestones and their onset during the progression from MetS to HF in this experimental model. We found that SHHF(cp/cp )but not SHHF(+/?) rats developed dyslipidemia, as early as 1.5 months of age. This early alteration in the lipidic profile was detectable concomitantly to impaired renal function (polyuria, proteinuria but no glycosuria) and reduced carotid distensibility as compared to SHHF(+/?) rats. By 3 months of age SHHFcp/cp animals developed severe obesity associated with dislipidemia and hypertension defining the onset of MetS. From 6 months of age, SHHF(+/?) rats developed concentric left ventricular hypertrophy (LVH) while SHHF(cp/cp) rats developed eccentric LVH apparent from progressive dilation of the LV dimensions. By 14 months of age only SHHF(cp/cp) rats showed significantly higher central systolic blood pressure and a reduced ejection fraction resulting in systolic dysfunction as compared to SHHF(+/?). In summary, the metabolic and hemodynamic mechanisms participating in the faster decline of cardiac functions in SHHF(cp/cp) rats are established long before their physiological consequences are detectable. Our results suggest that the molecular mechanisms triggered within the first three months after birth of SHHF(cp/cp) rats should be targeted preferentially by therapeutic interventions in order to mitigate the later HF development.

Indexed as

Disease Models, AnimalAnimalsBlood PressureDisease ProgressionEchocardiographyHeart FailureHemodynamicsHypertensionInsulin ResistanceKidneyMaleMetabolic SyndromePhenotypeRatsSystole

Identifiers

PMID24831821
PMCPMC4022510
OpenAlexW1970911056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.